Erleada is a successor to J&J’s Zytiga (abiraterone), which has gone off patent in the US and succumbing to generic competition – sales of the blockbuster were down nearly 60% in Q2 in the US ...

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing ...

Erleada plus ADT, compared with placebo plus ADT, achieved a 34% risk reduction in median time to second progression-free survival (PFS2), defined as time from randomisation to either disease ...

Erleada (apalutamide) is a brand-name drug prescribed for certain types of prostate cancer in adults. Erleada comes as a tablet that’s typically taken once per day. For these uses, Erleada may ...

The pharmaceuticals sales growth was led by continued market share gains for Darzalex, Erleada, Spravato, and Tremfya, among others. One of its top-selling drugs, Stelara, saw its revenue fall 6.6 ...

Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced ...